



INDOCO REMEDIES LIMITED

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email: compliance.officer@indoco.com

Web: www.indoco.com CIN: L85190MH1947PLC005913

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2018

(₹ In Lakhs)

Sr. No	Particulars	Quarter ended 30.09.2018 (Unaudited)	Quarter ended 30.06.2018 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Half year ended 30.09.2018 (Unaudited)	Half year ended 30.09.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	23,591	21,249	28,004	44,840	48,426	101,731
	(b) Other Operating Income	(28)	504	477	476	956	2,427
	Total Income from Operations (Net) (a+b)	23,563	21,753	28,481	45,316	49,382	104,158
2	Other Income	33	31	234	64	320	479
3	Total Income (1+2)	23,596	21,784	28,715	45,380	49,702	104,637
4	Expenses						
	(a) Cost of materials consumed	5,464	4,838	7,551	10,302	13,608	28,149
	(b) Purchases of stock-in-trade	2,143	1,710	1,499	3,853	3,284	6,460
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	355	581	975	936	244	330
	(d) Employee Benefits Expense	5,848	5,610	5,537	11,458	11,167	22,034
	(e) Research & Development Expense	1,275	1,321	1,175	2,596	2,532	5,349
	(f) Other Expenses	7,297	6,536	7,651	13,833	14,325	28,350
	(g) Finance Costs	501	718	697	1,219	1,306	2,351
	(h) Depreciation and Amortisation Expense	1,765	1,672	1,721	3,437	3,408	6,771
	Total Expenses	24,648	22,986	26,806	47,634	49,874	99,794
5	Profit/(Loss) before Tax (3-4)	(1,052)	(1,202)	1,909	(2,254)	(172)	4,843
6	Tax Expenses						
	- Current	-	-	-	-	-	1,107
	- Deferred	(522)	-	(67)	(522)	25	(1,006)
	- MAT Credit Adjustments	249	-	-	249	-	622
	Total Tax Expenses	(273)	-	(67)	(273)	25	723
7	Profit/(Loss) for the period (5-6)	(779)	(1,202)	1,976	(1,981)	(197)	4,120
8	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(3)	(3)	(5)	(6)	(10)	35
	ii) Income tax on relating to this item	1	1	2	2	3	(12)
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(2)	(2)	(3)	(4)	(7)	23
	Total Comprehensive income for the year (7+8)	(781)	(1,204)	1,973	(1,985)	(204)	4,143
9	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
10	Other Equity	-	-	-	-	-	65,713
11	Earnings per share (of ₹ 2/- each)						
	(a) Basic- in ₹	(0.85)	(1.30)	2.14	(2.15)	(0.21)	4.47
	(b) Diluted- in ₹	(0.85)	(1.30)	2.14	(2.15)	(0.21)	4.47

Notes :

1 Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th November, 2018.

2 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 30.09.2018 (Unaudited)	Quarter ended 30.06.2018 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Half year ended 30.09.2018 (Unaudited)	Half year ended 30.09.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
India	16,948	16,359	19,749	33,307	30,771	63,335
Outside India	6,643	4,890	8,255	11,533	17,655	38,396
Total	23,591	21,249	28,004	44,840	48,426	101,731

3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2018.

4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

5 STATEMENT OF ASSETS AND LIABILITIES

(₹ In Lakhs)

Sr. No	Particulars	As at 30.09.2018 (Unaudited)	As at 31.03.2018 (Audited)
A	ASSETS		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	41,958	44,101
	(b) Capital Work in Progress	9,456	7,578
	(c) Other Intangible Assets	4,441	4,772
	(d) Intangible Assets under Development	5,994	5,978
	(e) Financial Assets		
	(i) Investments	277	261
	(ii) Loans	150	107
	(iii) Others	1,790	1,601
	(f) Deferred Tax Assets (Net)	3,410	3,135
	(g) Income Tax Assets (Net)	546	307
	(h) Other Non-Current Assets	3,136	2,245
	Total - Non-Current Assets	71,158	70,085
2	Current Assets		
	(a) Inventories	18,647	19,323
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade Receivables	19,255	20,615
	(iii) Cash and Cash Equivalents	827	796
	(iv) Other Bank Balance	262	385
	(v) Loans	73	59
	(vi) Others	7	199
	(c) Other Current Assets	11,096	12,171
	Total - Current Assets	50,167	53,548
	Total - Assets	121,325	123,633
B	Equity and Liabilities		
1	Equity		
	(a) Equity Share Capital	1,843	1,843
	(b) Other Equity	62,617	65,713
	Total Equity	64,460	67,556
2	Liabilities		
a)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	12,272	12,328
	(ii) Other Financial Liabilities	732	711
	(b) Provisions	1,361	1,266
	(c) Other Non-Current Liabilities	250	250
	Total - Non-Current Liabilities	14,615	14,555
b)	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	9,877	10,993
	(ii) Trade Payables	14,100	14,945
	(iii) Other Financial Liabilities	13,051	10,220
	(b) Provisions	3,813	3,820
	(c) Other Current Liabilities	1,409	1,544
	Total - Current Liabilities	42,250	41,522
	Total, Liabilities	56,865	56,077
	Total - Equity and Liabilities	121,325	123,633

By Order of the Board
For Indoco Remedies Ltd
s/d

Place : Mumbai
Date : 13th November,2018

Suresh G. Kare
Chairman